Baxter International (BAX) : The total negative money flow of $2.53 million on Wednesday indicates selling on strength. The inflow of money on upticks was $13.12 million, compared to $15.64 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.84. The negative money flow of $1.98 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $1.98 million. The price action in the Baxter International (BAX) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $47.41 with a gain of $0.08 , a change of 0.17% over the previous days close. The stock registered -0.17% for the week.
Baxter International Inc. is up 7.21% in the last 3-month period. Year-to-Date the stock performance stands at 26.7%.
Baxter International (BAX) has an average broker rating of 2.78, which is interpreted as a Hold, as rated by 12 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 9 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
Baxter International (NYSE:BAX): The stock opened at $47.39 and touched an intraday high of $47.94 on Wednesday. During the day, the stock corrected to an intraday low of $47.16, however, the bulls stepped in and pushed the price higher to close in the green at $47.92 with a gain of 1.25% for the day. The total traded volume for the day was 3,489,139. The stock had closed at $47.33 in the previous trading session.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.